IDEAYA Biosciences logo
IDEAYA Biosciences
IDYA | NASDAQ
Chart Builder DCF Calculator
$30.36
-$1.47 (-4.62%)
At close: Nov 16, 2026, 4:00 PM ET
$30.36
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

IDEAYA Biosciences Company Profile

Company profile explained

Company Profile

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

Key Executives

Name Position
Yujiro S. Hata Founder, President, CEO & Chairman
Douglas Snyder Chief Legal Officer
Joshua Bleharski Chief Financial Officer
Paul A. Barsanti Chief Technology Officer
Andres Ruiz Briseno Chief Accounting Officer
Daniel A. Simon Chief Business Officer
Darrin Beaupre Chief Medical Officer
Francine Zelaya Senior VP & Head of Human Resources
Jasgit Sachdev Senior Vice President of Late Phase Clinical Development & Strategy
Michael A. White President of Research & Development
Mick O'Quigley Senior Vice President of Medical Writing & Project Management
Stuart Dorman Chief Commercial Officer

Latest SEC Filings

Date Type Title
Oct 08, 2026 4 Filing
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 04, 2026 10-Q Quarterly Report
Aug 04, 2026 8-K Current Report
Jul 31, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 09, 2026 4 Filing
Jun 23, 2026 8-K Current Report
Jun 18, 2026 4 Filing
Jun 18, 2026 4 Filing
Jun 18, 2026 4 Filing
View All SEC Filings ➞
IDEAYA Biosciences
IDEAYA Biosciences logo
Country United States
IPO Date May 23, 2019
Industry Biotechnology
Sector Healthcare
Employees 145
CEO Yujiro S. Hata

Contact Details

7000 Shoreline Court South San Francisco, California 94080 United States

Stock Details

Ticker Symbol IDYA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001676725
CUSIP Number 45166A102
ISIN Number US45166A1025
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.